Literature DB >> 25712233

Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management.

Erika De Sousa Amorim1, Miquel Blasco2, Luis Quintana2, Manel Sole3, Santiago Rodríguez de Cordoba4, Josep Maria Campistol2.   

Abstract

Pregnancy-associated atypical hemolytic uremic syndrome is a systemic disease associated with high morbidity and mortality rates, caused by dysregulation of the alternative complement pathway, leading to uncontrolled complement activation resulting in thrombotic microangiopathy. This condition can be effectively treated by anti-C5 therapy, which controls complement activation. Treatment can be safely discontinued after complete remission and resolution of the precipitating cause, especially in patients with a low-risk genetic profile.

Entities:  

Keywords:  Eculizumab; Hemolytic uremic syndrome; Post-partum; Pregnancy

Mesh：

Substances：

Year:  2015        PMID： 25712233     DOI： 10.1007/s40620-015-0173-5

Source DB:  PubMed          Journal:  J Nephrol        ISSN： 1121-8428            Impact factor:   3.902


  16 in total

1.  Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab.

Authors:  Stefan Zschiedrich; Eric P Prager; E Wolfgang Kuehn
Journal:  Ann Intern Med       Date:  2013-07-02       Impact factor: 25.391

2.  Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome.

Authors:  Carolina Cañigral; Federico Moscardó; Cristina Castro; Azucena Pajares; Aima Lancharro; Pilar Solves; Javier de la Rubia; Nelly Carpio; Miguel A Sanz
Journal:  Ann Hematol       Date:  2013-12-05       Impact factor: 3.673

3.  Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

Authors:  Elena Bresin; Erica Rurali; Jessica Caprioli; Pilar Sanchez-Corral; Veronique Fremeaux-Bacchi; Santiago Rodriguez de Cordoba; Sheila Pinto; Timothy H J Goodship; Marta Alberti; David Ribes; Elisabetta Valoti; Giuseppe Remuzzi; Marina Noris
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

4.  The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy.

Authors:  J S Dashe; S M Ramin; F G Cunningham
Journal:  Obstet Gynecol       Date:  1998-05       Impact factor: 7.661

5.  Irreversible post-partum renal failure. A new syndrome.

Authors:  J S Robson; A M Martin; V Ruckley; M K Macdonald
Journal:  Q J Med       Date:  1968-07

6.  Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.

Authors:  Fadi Fakhouri; Lubka Roumenina; François Provot; Marion Sallée; Sophie Caillard; Lionel Couzi; Marie Essig; David Ribes; Marie-Agnès Dragon-Durey; Frank Bridoux; Eric Rondeau; Veronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 10.121

Review 7.  How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  J N George
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

8.  Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.

Authors:  Gianluigi Ardissino; Sara Testa; Ilaria Possenti; Francesca Tel; Fabio Paglialonga; Stefania Salardi; Silvana Tedeschi; Mirco Belingheri; Massimo Cugno
Journal:  Am J Kidney Dis       Date:  2014-03-19       Impact factor: 8.860

Review 9.  Atypical hemolytic uremic syndrome.

Authors:  Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Orphanet J Rare Dis       Date:  2011-09-08       Impact factor: 4.123

10.  Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice.

Authors:  Yahsou Delmas; Cécile Bordes; Chantal Loirat; Véronique Frémeaux-Bacchi; Christian Combe
Journal:  Clin Kidney J       Date:  2013-04
View more
  15 in total

1.  Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.

Authors:  Sami Alobaidi; Ammar AlDabbagh; Amany Alamoudi; Murad Almowarey; Ahmed Akl
Journal:  CEN Case Rep       Date:  2019-02-04

2.  Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome.

Authors:  Martina Gaggl; Christof Aigner; Dorottya Csuka; Ágnes Szilágyi; Zoltán Prohászka; Renate Kain; Natalja Haninger; Maarten Knechtelsdorfer; Raute Sunder-Plassmann; Gere Sunder-Plassmann; Alice Schmidt
Journal:  J Am Soc Nephrol       Date:  2017-12-27       Impact factor: 10.121

3.  HELLP syndrome: a diagnostic conundrum with severe complications.

Authors:  Devika Rao; Nikulkumar Kumar Chaudhari; Robert Michael Moore; Belinda Jim
Journal:  BMJ Case Rep       Date:  2016-08-17

Review 4.  Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.

Authors:  Savino Sciascia; Massimo Radin; Jinoos Yazdany; Maria Tektonidou; Irene Cecchi; Dario Roccatello; Maria Dall'Era
Journal:  Rheumatol Int       Date:  2017-03-03       Impact factor: 2.631

Review 5.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

6.  Hemolytic Uremic Syndrome in Pregnancy and Postpartum.

Authors:  Alexandra Bruel; David Kavanagh; Marina Noris; Yahsou Delmas; Edwin K S Wong; Elena Bresin; François Provôt; Vicky Brocklebank; Caterina Mele; Giuseppe Remuzzi; Chantal Loirat; Véronique Frémeaux-Bacchi; Fadi Fakhouri
Journal:  Clin J Am Soc Nephrol       Date:  2017-06-08       Impact factor: 8.237

7.  Pregnant Woman with Atypical Hemolytic Uremic Syndrome Delivered a Healthy Newborn under Eculizumab Treatment.

Authors:  Erol Demir; Halil Yazici; Yasemin Ozluk; Isin Kilicaslan; Aydin Turkmen
Journal:  Case Rep Nephrol Dial       Date:  2016-12-20

8.  Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.

Authors:  Manuel Macia; Fernando de Alvaro Moreno; Tina Dutt; Ingela Fehrman; Karine Hadaya; Christoph Gasteyger; Nils Heyne
Journal:  Clin Kidney J       Date:  2016-12-22

Review 9.  Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Authors:  Arif Asif; Ali Nayer; Christian S Haas
Journal:  J Nephrol       Date:  2016-11-15       Impact factor: 3.902

Review 10.  Critical appraisal of eculizumab for atypical hemolytic uremic syndrome.

Authors:  Lilian M Pereira Palma; Craig B Langman
Journal:  J Blood Med       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.